Abstract. Eighteen patients treated with oxybutynin chloride are presented. The effect of the drug on the hyperactive detrusor is shown and discussed. Side effects and limita tions are described and related to treatment.
Introduction
THE problem of the hyperactive detrusor (Andersen & Bradley, 1977) of varying aetiologies is a very common urologic occurrence. Many various pharmacologic agents are available for management of this distressing situation. Oxybutynin chloride (Ditropan) is the latest in a long series of attempts to find an agent which will have greater specificity for the detrusor muscle with fewer systemic effects. This drug has been shown to have two main mechanisms of action: (I) cholinergic blockade, and (2) direct spasmolytic activity on smooth muscle (Frederichs et al., 1975) . Dickno and Lapides (1972) have shown the clinical effectiveness of oxybutynin chloride. Their findings have been supported by Mulcahy, James and McRoberts (1977) , and Thomson and Lauvetz (1976) . We have treated 18 patients who suffered from hyperactive detrusor reflexes using oxybutynin chloride. We present our findings and discuss the uses and limitations of this agent.
Methods
Eighteen patients, nine male and nine female, between the ages of 9 and 74 with a mean age of 47 ± 18 ·7 years are included in this report. Seven of these patients had documented injury to the spinal cord with neurologic findings of complete or incomplete spinal cord injuries. In seven cases the bladders, as shown by cystometrogram, were of the spastic upper motor neurone type. Three patients had brain damage; one patient a brain concussion, an.d the other two patients cerebral vascular accidents. Two patients had small capacity bladders as a result of long-standing indwelling catheter drainage. The remaining six patients had hyperactive detrusors with varying complaints of urgency, frequency, and nocturia (Table I) . Pre-examination medications in all spinal cord injured patients in cluded Hypprex and vitamin C for urine acidification. One patient in this group with indwelling catheters received benactyzine methylbromide (Paragone), an anticholinergic agent, 25 mg three times daily. This was stopped prior to the institution of oxybutynin chloride. All other patients received no medication prior to examination. Four patients had indwelling catheters, one brain injured, two with spinal cord injury, and one with a hyperactive detrusor of unknown aetiology.
All examinations were performed with a carbon dioxide cystometer. Patients voided and then were catheterised with sterile technique using the non-touch method (Guttmann, 1973) . Residual urines were drained and measured, and then CO2 was introduced at a flow rate of 120 ml per min. Patients were asked to report the first urge to void which was recorded as the first sensation of filling (FSF).
Patients were then instructed to tolerate the increasing feeling of fullness and urgency until they were absolutely unable and then to urinate. With a rise in intrabladder pressure 30 cm H20 above the initial bladder pressure, either voluntarily or involuntarily, the examination was terminated. This point was used to determine the total bladder capacity (VOL). Oxybutynin chloride in the dosage of 5 mg three times daily was then instituted, and after I month of therapy, repeat examinations were performed. Bladder types were classified according to Anderson and Bradley (1977) .
Results
Twelve of the 18 patients tolerated oxybutynin chloride easily. In all cases the chief complaints of frequency and urgency markedly subsided. Patients reported a decrease in nocturia or an ability to function for longer periods between voiding. Three patients showed large increases in residual urines. Of the four patients with indwelling catheters prior to the institution of therapy, only I patient, patient R, was able to achieve a catheter-free state. Patient Q had a penile scrotal fistula resistant to surgical closure and requiring a suprapubic catheter. Patient 0 could not tolerate the drug and patient B died soon after the follow-up from a second cerebral vascular insult (see Table II ). Table III shows the improvement in FSF and VOL. Mean initial was 83 ± 43 ml and the mean initial VOL was 147 ± 72 ml. Follow-up studies in 13 patients showed a mean FSF of 141 ± 53 ml and a mean VOL of 290 ± 87 ml. In all cases an improvement in follow-up VOL was noted as compared to the initial VOL. Patient E is a 9-year-old girl whose total bladder capacity certainly is much less than the normal adult volume. Patient B is a man with a large prostate gland who was on catheter drainage. Five patients had no follow-up study. Four of these patients stopped therapy for various reasons as discussed below. The fifth man, patient Q, had a suprapubic catheter inserted as described above. Six of the 18 patients were unable to tolerate oxybutynin chloride. Table IV shows the varying reasons for this. Four of the patients complained of symptoms seemingly related to the anticholinergic effects of the drug. The other 2 patients complained of direct allergic reactions. Two of the patients who stopped the drug, patients C and D, did show improvement in bladder function before being forced to interrupt treatment.
Discussion
Our results in this study are in agreement with those shown in previous publications (Mulcahy, James & McRoberts, 1977; Thomson & Lauvetz, 1976) . We note a 77 per cent improvement in the FSF with oxybutynin chloride and a 97 per cent improvement in the VOL with this drug (Table III) . While not as dramatic an improvement as shown by Thompson and Lauvetz (1976) because of the heterogeneity of the group, this certainly is a significant change. In con junction with this improvement in objective findings, we also noted a marked decrease in subjective complaints. Although three patients did have a marked increase in residual urines, these residual volumes were reduced by better emptying techniques. There is no doubt that oxybutynin chloride is an excellent addition to the pharmacologic management of the hyperactive detrusor.
Most disturbing to us, however, is the finding that 33 per cent of our patients could not tolerate oxybutynin chloride. Their complaints as listed in Table IV were severe enough in all six cases to cause the patient to stop the drug ingestion without consulting the physician. Four of the patients had typical systemic effects of anticholinergic agents. In the cases of patients J and 0, where the side effects were typical of all anticholinergic drugs, i.e. abdominal discomfort, fullness, and constipation, no amount of reassurance or explanation could convince these patients to reduce the dosage and continue therapy. Two other patients had direct allergic reactions of itching and pain in surgical scars. This may be related to histamine release and the stimulation of fibroblasts. In both these cases, the symptoms subsided completely after cessation of the drug. Contrary to the reports cited above (Diokno & Lapides, 1972; Thompson & Lauvetz, 1976;  
